Sarepta Therapeutics (SRPT) Competitors $114.23 +3.73 (+3.38%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SRPT vs. JAZZ, IONS, RARE, MRTX, PTCT, BNTX, TEVA, BGNE, VTRS, and MRNAShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), and Moderna (MRNA). These companies are all part of the "medical" sector. Sarepta Therapeutics vs. Jazz Pharmaceuticals Ionis Pharmaceuticals Ultragenyx Pharmaceutical Mirati Therapeutics PTC Therapeutics BioNTech Teva Pharmaceutical Industries BeiGene Viatris Moderna Sarepta Therapeutics (NASDAQ:SRPT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership. Do insiders & institutionals believe in SRPT or JAZZ? 86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, SRPT or JAZZ? Sarepta Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Do analysts recommend SRPT or JAZZ? Sarepta Therapeutics presently has a consensus price target of $181.33, indicating a potential upside of 58.74%. Jazz Pharmaceuticals has a consensus price target of $175.33, indicating a potential upside of 38.42%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Sarepta Therapeutics is more favorable than Jazz Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 0 Sell rating(s) 1 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 3.00Jazz Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is SRPT or JAZZ more profitable? Jazz Pharmaceuticals has a net margin of 11.60% compared to Sarepta Therapeutics' net margin of 7.43%. Jazz Pharmaceuticals' return on equity of 29.30% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Jazz Pharmaceuticals 11.60%29.30%9.72% Does the media prefer SRPT or JAZZ? In the previous week, Jazz Pharmaceuticals had 22 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 33 mentions for Jazz Pharmaceuticals and 11 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.98 beat Jazz Pharmaceuticals' score of 0.65 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 15 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Does the MarketBeat Community believe in SRPT or JAZZ? Sarepta Therapeutics received 339 more outperform votes than Jazz Pharmaceuticals when rated by MarketBeat users. However, 80.71% of users gave Jazz Pharmaceuticals an outperform vote while only 75.45% of users gave Sarepta Therapeutics an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes146075.45% Underperform Votes47524.55% Jazz PharmaceuticalsOutperform Votes112180.71% Underperform Votes26819.29% Which has better earnings and valuation, SRPT or JAZZ? Jazz Pharmaceuticals has higher revenue and earnings than Sarepta Therapeutics. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.24B8.78-$535.98M$1.2591.38Jazz Pharmaceuticals$3.83B2.00$414.83M$7.1017.84 SummarySarepta Therapeutics beats Jazz Pharmaceuticals on 10 of the 19 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.91B$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio91.3811.01105.0417.81Price / Sales8.78361.871,235.79158.52Price / CashN/A52.5940.3536.29Price / Book8.9410.377.086.50Net Income-$535.98M$153.60M$119.58M$226.22M7 Day Performance9.27%4.59%2.25%4.03%1 Month Performance-12.05%-6.28%-2.34%4.92%1 Year Performance36.36%33.39%33.95%29.30% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.9633 of 5 stars$114.23+3.4%$181.33+58.7%+36.4%$10.91B$1.24B91.381,314Analyst DowngradeJAZZJazz Pharmaceuticals4.8871 of 5 stars$125.10+4.9%$175.33+40.2%+4.1%$7.56B$3.83B17.342,800Analyst ForecastNews CoverageGap UpIONSIonis Pharmaceuticals4.087 of 5 stars$33.83-4.4%$60.65+79.3%-31.4%$5.34B$788M-13.86800RAREUltragenyx Pharmaceutical4.5863 of 5 stars$46.02-0.8%$87.46+90.1%+23.6%$4.25B$434.25M-7.241,276Analyst ForecastMRTXMirati Therapeutics0.5692 of 5 stars$58.70flat$59.00+0.5%N/A$4.12B$12.44M-4.80587Analyst ForecastPTCTPTC Therapeutics2.5891 of 5 stars$42.89+2.2%$42.00-2.1%+100.0%$3.31B$937.82M-7.061,410Analyst DowngradeBNTXBioNTech2.634 of 5 stars$108.20+5.9%$138.79+28.3%+15.5%$25.94B$4.13B-51.526,133Analyst ForecastTEVATeva Pharmaceutical Industries3.0106 of 5 stars$17.08+0.3%$19.67+15.1%+81.0%$19.35B$15.85B-20.0337,851Insider TradeBGNEBeiGene3.1896 of 5 stars$194.56+0.2%$247.07+27.0%+4.2%$18.95B$2.46B-23.5810,600Analyst DowngradeVTRSViatris1.4394 of 5 stars$13.26+0.9%$13.33+0.6%+42.7%$15.82B$15.43B-17.9138,000News CoverageMRNAModerna4.5755 of 5 stars$38.40+4.0%$84.00+118.7%-47.4%$14.78B$6.85B-6.355,600Analyst ForecastOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Jazz Pharmaceuticals Competitors Ionis Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Mirati Therapeutics Competitors PTC Therapeutics Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Viatris Competitors Moderna Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SRPT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRPT Stock Alerts